Breaking up the CD8+ T cell: Treg pas de deux

Chenyu Zhang; Alissa Bockman; Michel DuPage

doi:10.1016/j.ccell.2024.05.016

Breaking up the CD8⁺ T cell: Treg pas de deux

Cancer Cell. 2024 Jun 10;42(6):941-942. doi: 10.1016/j.ccell.2024.05.016.

Authors

Chenyu Zhang¹, Alissa Bockman¹, Michel DuPage²

Affiliations

¹ Division of Immunology and Molecular Medicine, Department of Molecular and Cell Biology, University of California Berkeley, Berkeley, CA, USA.
² Division of Immunology and Molecular Medicine, Department of Molecular and Cell Biology, University of California Berkeley, Berkeley, CA, USA. Electronic address: [email protected].

PMID: 38861931
DOI: 10.1016/j.ccell.2024.05.016

Abstract

Checkpoint blockade immunotherapies, such as anti-programmed death-1 (PD-1), unleash anti-tumor CD8⁺ T cell responses but may also induce immunosuppressive regulatory T cells (Tregs). In this issue of Cancer Cell, Geels et al. uncover that anti-PD-1 leads to Treg expansion via interleukin-2 (IL-2)-producing CD8⁺ T cells. Combining anti-PD-1 with anti-ICOSL interrupts this crosstalk, thereby enhancing tumor control.

Publication types

Kommentar

MeSH terms

Animals
CD8-Positive T-Lymphocytes* / immunology
Humans
Immune Checkpoint Inhibitors / pharmacology
Immune Checkpoint Inhibitors / therapeutic use
Immunotherapy / methods
Interleukin-2 / immunology
Neoplasms / immunology
Programmed Cell Death 1 Receptor / antagonists & inhibitors
Programmed Cell Death 1 Receptor / immunology
T-Lymphocytes, Regulatory* / immunology

Substances

Programmed Cell Death 1 Receptor
Interleukin-2
Immune Checkpoint Inhibitors